Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 817615, 7 pages
http://dx.doi.org/10.1155/2015/817615
Research Article

Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure

1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Department of Cardiology, Yinzhou People’s Hospital, Medical School of Ningbo University, Ningbo 315040, China
3Clinical Laboratory Center, Yinzhou People’s Hospital, Medical School of Ningbo University, Ningbo 315040, China

Received 23 July 2015; Revised 13 September 2015; Accepted 5 October 2015

Academic Editor: Hua Zhu

Copyright © 2015 Haibo Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Stewart, K. MacIntyre, D. J. Hole, S. Capewell, and J. J. V. McMurray, “More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure,” European Journal of Heart Failure, vol. 3, no. 3, pp. 315–322, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Lamblin, F. Mouquet, B. Hennache et al., “High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure,” European Heart Journal, vol. 26, no. 21, pp. 2245–2250, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Kardys, A. M. Knetsch, G. S. Bleumink et al., “C-reactive protein and risk of heart failure. The Rotterdam study,” American Heart Journal, vol. 152, no. 3, pp. 514–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. E. S. Williams, S. J. Shah, S. Ali, B. Y. Na, N. B. Schiller, and M. A. Whooley, “C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study,” European Journal of Heart Failure, vol. 10, no. 1, pp. 63–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Agrawal, “CRP after 2004,” Molecular Immunology, vol. 42, no. 8, pp. 927–930, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Garianda, E. Hirsch, S. Bozza et al., “Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response,” Nature, vol. 420, no. 6912, pp. 182–186, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Breviario, E. M. D'Aniello, J. Golay et al., “Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component,” Journal of Biological Chemistry, vol. 267, no. 31, pp. 22190–22197, 1992. View at Google Scholar · View at Scopus
  9. M. Introna, V. Vidal Alles, M. Castellano et al., “Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites,” Blood, vol. 87, no. 5, pp. 1862–1872, 1996. View at Google Scholar · View at Scopus
  10. M. S. Rolph, S. Zimmer, B. Bottazzi, C. Garlanda, A. Mantovani, and G. K. Hansson, “Production of the long pentraxin PTX3 in advanced atherosclerotic plaques,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. e10–e14, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Savchenko, M. Imamura, R. Ohashi et al., “Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions,” Journal of Pathology, vol. 215, no. 1, pp. 48–55, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Haibo, G. Xiaofang, W. Chunming et al., “Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation,” Mediators of Inflammation, vol. 2014, Article ID 963096, 7 pages, 2014. View at Publisher · View at Google Scholar
  13. J. Matsubara, S. Sugiyama, T. Nozaki et al., “Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction,” Journal of the American College of Cardiology, vol. 57, no. 7, pp. 861–869, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Latini, L. Gullestad, S. Masson et al., “Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials,” European Journal of Heart Failure, vol. 14, no. 9, pp. 992–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Matsubara, S. Sugiyama, T. Nozaki et al., “Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction,” Journal of the American Heart Association, vol. 3, no. 4, Article ID e000928, 2014. View at Publisher · View at Google Scholar
  16. S. Suzuki, Y. Takeishi, T. Niizeki et al., “Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure,” American Heart Journal, vol. 155, no. 1, pp. 75–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Inoue, A. Sugiyama, P. C. Reid et al., “Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 161–167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Kotooka, T. Inoue, S. Aoki, M. Anan, H. Komoda, and K. Node, “Prognostic value of pentraxin 3 in patients with chronic heart failure,” International Journal of Cardiology, vol. 130, no. 1, pp. 19–22, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Yamasaki, M. Kurimura, T. Kasai, M. Sagara, T. Kodama, and K. Inoue, “Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 4, pp. 471–477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Beygui, M. Anguita, U. Tebbe et al., “A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms,” Heart Failure Reviews, vol. 20, no. 5, pp. 545–552, 2015. View at Publisher · View at Google Scholar
  21. T. B. Horwich, J. Patel, W. R. MacLellan, and G. C. Fonarow, “Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure,” Circulation, vol. 108, no. 7, pp. 833–838, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Tsutamoto, C. Kawahara, K. Nishiyama et al., “Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure,” American Heart Journal, vol. 159, no. 1, pp. 63–67, 2010. View at Publisher · View at Google Scholar · View at Scopus